Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Assets (2016 - 2025)

Plus Therapeutics has reported Non-Current Assets over the past 16 years, most recently at $1.2 million for Q4 2025.

  • Quarterly Non-Current Assets fell 15.94% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 26.73% year-over-year, with the annual reading at $1.2 million for FY2025, 15.94% down from the prior year.
  • Non-Current Assets was $1.2 million for Q4 2025 at Plus Therapeutics, up from $1.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $2.9 million in Q1 2021 and troughed at $1.1 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $1.8 million (2023), against an average of $1.9 million.
  • Year-over-year, Non-Current Assets dropped 0.05% in 2024 and then crashed 37.99% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $2.3 million in 2021, then fell by 9.17% to $2.0 million in 2022, then dropped by 24.2% to $1.6 million in 2023, then dropped by 11.58% to $1.4 million in 2024, then dropped by 15.94% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Non-Current Assets are $1.2 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025).